Explanation

Long-acting injectable (LAI) antipsychotics present unique informed consent considerations that go beyond standard medication consent. The most significant difference is irreversibility — once injected, the medication cannot be removed and will remain pharmacologically active for the duration of the injection cycle (typically 2-4 weeks for most formulations, up to 3 months for some). This has important implications for managing side effects: if a patient develops akathisia, extrapyramidal symptoms, or other adverse effects from an LAI, these effects cannot be quickly eliminated by stopping the medication. The patient needs to understand this commitment before consenting. Additional specific consent elements include: potential injection site reactions (pain, induration, rarely sterile abscess), the need for a consistent dosing schedule, the transition period from oral to injectable medication, and the extended observation period that may be required with some formulations. The PMHNP should ensure the patient understands all of these factors before proceeding.

Key Takeaway

Long-acting injectable antipsychotics require specific informed consent about irreversibility, prolonged duration, and the implications for managing side effects.